Overview

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the clinical efficacy of Levetiracetam in the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in an open label study.
Phase:
N/A
Details
Lead Sponsor:
Berkshire Health Systems
Collaborator:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam